Skip to main content
REGN
NASDAQ Life Sciences

瑞吉恩的Cemdisiran 3期数据发表，提交了广泛性肌无力（gMG）的监管申请

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
8
Price
$742.815
Mkt Cap
$78.518B
52W Low
$476.487
52W High
$821.11
Market data snapshot near publication time

summarizeSummary

瑞吉恩宣布了其研究性药物Cemdisiran在广泛性肌无力（gMG）的3期NIMBLE试验中发布了详细的阳性结果。这些数据发表在The Lancet上，并在美国神经学学会上进行了演讲，表明了快速、深入和持续的疾病控制，采用方便的皮下每12周给药，达到其主要和关键次要终点。这是在2025年8月份分享的初步阳性顶级数据之后，提供了对该药物的疗效和安全性特征的全面验证。至关重要的是，已经提交了美国监管申请，将Cemdisiran定位为潜在的第一类siRNA用于gMG。这代表着瑞吉恩管道的重大进展，可能会开启新的、重要的收入来源。投资者现在将关注监管审查过程和即将举行的投资者活动，以获取进一步的见解。

在该公告发布时，REGN的交易价格为$742.82，交易所为NASDAQ，所属行业为Life Sciences，市值约为$785.2亿。 52周交易区间为$476.49至$821.11。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed REGN - Latest Insights

REGN
Apr 29, 2026, 6:54 AM EDT
Filing Type: 10-Q
Importance Score:
8
Regeneron Reports Mixed Q1 Results, Authorizes $3B Buyback, Details Government Pricing Deals & Key Legal Updates
Sentiment: Neutral
View Wiseek Article
REGN
Apr 29, 2026, 6:50 AM EDT
Filing Type: 8-K
Importance Score:
8
Regeneron Reports Strong Q1 Results, Authorizes New $3.0 Billion Share Repurchase, and Secures Strategic Government Pricing Agreement
Sentiment: Positive
View Wiseek Article
REGN
Apr 29, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Regeneron Posts 19% Revenue Growth in Q1, Non-GAAP EPS Up 15% Amidst GAAP Decline
Sentiment: Positive
View Wiseek Article
REGN
Apr 24, 2026, 12:25 AM EDT
Source: dpa-AFX
Importance Score:
8
Regeneron's Otarmeni Gene Therapy Approved by FDA for Genetic Hearing Loss
Sentiment: Positive
View Wiseek Article
REGN
Apr 23, 2026, 12:42 PM EDT
Source: Reuters
Importance Score:
8
FDA Approves Regeneron's Gene Therapy for Inherited Deafness
Sentiment: Positive
View Wiseek Article
REGN
Apr 23, 2026, 1:30 AM EDT
Source: Reuters
Importance Score:
7
Dupixent Sales Soar 30.8%, Beating Estimates in Sanofi's Q1 Report
Sentiment: Positive
View Wiseek Article
REGN
Apr 22, 2026, 5:30 PM EDT
Source: GlobeNewswire
Importance Score:
8
Dupixent Gains U.S. Approval for Young Children with Chronic Spontaneous Urticaria
Sentiment: Positive
View Wiseek Article
REGN
Apr 21, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Regeneron's Cemdisiran Phase 3 Data Published, Regulatory Filing Submitted for gMG
Sentiment: Positive
View Wiseek Article
REGN
Apr 13, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Dupixent Secures EU Approval for Young Children with Chronic Urticaria, Expanding Key Market
Sentiment: Positive
View Wiseek Article
REGN
Apr 12, 2026, 7:08 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Regeneron Forms Radiopharma Partnership with Telix, Potentially Worth Over $2.1 Billion
Sentiment: Positive
View Wiseek Article